Bullous pemphigoid after anti–programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

Camille Hua, Lise Boussemart, Christine Mateus et al. · JAMA Dermatology · 2015 · 650 citations

Medicine, Dermatology, Oncology +17

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

Martina Sanlorenzo, Igor Vujic, Adil Daud et al. · JAMA Dermatology · 2015 · 452 citations · Full text

Medicine, Oncology, Pharmacology +15

Challenges of Guarantee-Time Bias

Anita Giobbie‐Hurder, Richard D. Gelber, Meredith M. Regan · Journal of Clinical Oncology · 2013 · 448 citations · Full text

Public Health, Biostatistics, Pharmacotherapy +14

Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy

Jacob Siegel, Mariam Totonchy, William Damsky et al. · Journal of the American Academy of Dermatology · 2018 · 204 citations

Medicine, Oncology, Pathology +17

Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study

Charles Kyung Min Lee, Shufeng Li, Duy Tran et al. · Journal of the American Academy of Dermatology · 2018 · 117 citations · Full text

Medicine, Dermatology, Oncology +16